REVIEW ARTICLE

Mastocytosis: a rare case of anaphylaxis in paediatric age and literature review

I. Silva^a, S. Carvalho^a, P.L. Pinto^a, S. Machado^b and J. Rosado Pinto^a

^aDepartment of Immunoallergy. Dona Estefânia Hospital. Lisbon. ^bDepartment of Dermatology. Santo António do Porto Hospital. Oporto. Portugal.

ABSTRACT

The term "mastocytosis" denotes a heterogeneous group of disorders characterised by abnormal growth and accumulation of mast cells (MC) in one or more organ systems. Symptoms result from MC chemical mediator's release, pathologic infiltration of neoplastic MC in tissues or both. Multiple molecular, genetic and chromosomal defects seem to contribute to an autonomous growth, but somatic c-kit D816V mutation is more frequently encountered, especially in systemic disease.

We present a literature review of mastocytosis and a rare case report of an 18 month-old-girl with a bullous dermatosis, respiratory distress and anaphylaxis, as clinical manifestations of mastocytosis.

The developments of accepted classification systems and novel useful markers allowed a re-evaluation and updating of the classification of mastocytosis. In paediatric age cutaneous forms of disease prevail and may regress spontaneously. SM is more frequently diagnosed in adults and is a persistent (clonal) disease of bone marrow. The clinical course in these patients is variable.

Today diagnostic criteria for each disease variant are reasonably well defined. There are, however, peculiarities, namely in paediatric age, that makes the diagnostic approach difficult. Systemic disease may pose differential diagnostic problems resulting from multiple organ systems involvement. Conversely, the "unexplained" appearance of those symptoms with no skin lesions should raise the suspicion of MC disease.

This case is reported in order to stress the clinical severity and difficult diagnostic approach that paediatric mastocytosis may assume.

Key words: Mast cell. Mastocytosis. Classification. Criteria. Diagnosis. Childhood. Anaphylaxis. Review.

INTRODUCTION

In 1869, Nettleship and Tay first described the typical mastocytosis lesions (*urticaria pigmentosa*) as a rare form of urticaria.¹ Soon after the discovery of mast cells (MC), by Paul Ehrlich in 1879, these lesions were found to contain focal accumulations of MC.² However, it was not until 1949 that Ellis described the systemic variant of the disease with involvement of visceral organs.³

DEFINITION

The term "mastocytosis" denotes a heterogeneous group of disorders characterised by abnormal growth and accumulation of MC in one or more organ systems. It is also described as a neoplastic disease involving MC and their progenitors CD34+.⁴

Correspondence:

Isabel Silva
Av. Rui Grácio, n.º 59, 1.º esquerdo
2855-577 Corroios, Portugal
E-mail address: isacostasilva@gmail.com
Tel.: + 351966200463
Fax: + 351213126654

EPIDEMIOLOGY

Current estimates on prevalence of mastocytosis range from 1 in 1000 to 8000 patients in the dermatology office.⁵ In children approximately 5.4 cases per 1000 children are treated in dermatological clinics.⁶ Rosbotham et al estimated that there are two new cases per year in a population of 300,000 corresponding to an incidence of 0.000667 %.⁷

Mastocytosis occurs equally in both sexes and has been described in different ethnic groups, although there are more reports in caucasians.⁸

PATHOPHYSIOLOGY

MC are haematopoietic cells that reside in vascularized tissues, namely the connective tissues, often in the vicinity of smaller or larger blood vessels or nerve fibres.^{9,10} They are derived from multipotent hematopoietic progenitors CD34+, detectable in bone marrow as well as peripheral blood. Subsequently they distribute in the blood and transmigrate through the endothelial barrier into tissues before undergoing terminal differentiation and maturation.^{11,12} During differentiation MC acquire distinct morphologic and phenotypic properties with four defined stages of maturation: the non-granulated (tryptase-positive) blast cell; the metachromatic blast cell; the promastocyte/atypical MC type II and the mature MC.¹³ Several cytokines and the local microenvironment are considered to contribute to mastopoiesis. A pivotal cytokine in this process, the principle MC growth factor, is the Stem Cell (SCF) or kit-ligand.¹⁴⁻¹⁸ The effects of SCF on MC and their progenitors are mediated through a specific MC's receptor – transmembrane tyrosine kinase receptor, KIT or CD117.¹² This is in turn encoded by the c-kit proto-oncogene.^{12,19} Therefore, a “gain-of-function mutations” in the c-kit gene might be associated to enhanced growth and resistance to apoptosis of MC and their progenitors.²⁰ Several c-kit mutations have been identified.¹⁰ The point mutation D816V (Asp-816-Val) is the most frequently detected (> 80 % of all patients with SM).²¹⁻²⁴ Apparently additional defects are needed (molecular, genetic and chromosomal) in order for an autonomous cellular growth to occur.²⁵⁻²⁷ In contrast to sporadic cases, patients with familial Mastocytosis usually fail to express c-kit mutations,²² associated with resistance to imatinib.²⁸ Yet, a novel c-kit mutation has been identified in familial responsive to imatinib therapy.²⁷ The heterogeneity of c-kit mutations, and consequent clinical heterogeneity (age of onset of disease, patterns of skin disease, degree of organic involvement, hematopathology, me-

diator levels, response to therapy and prognosis), makes genotype-phenotype correlations characterization difficult.^{29,30} At least four ways have been suggested: single mutation at codon 816; sequential mutations (mutation at codon 816 allows further mutations); simultaneous mutations (others than 816 mutation) and chromosomal instability (predisposing to mutation at codon 816 and others).²⁹

Another important pathogenic aspect (in SM) is the abnormal expression of cell surface adhesion antigens CD2 (LFA-2) and CD25, identified by multicoloured flow cytometry.^{31,32} The most immature MC progenitors (both normal and neoplastic) express CD13, CD34 and CD117.

MC are easily recognisable by their metachromatic intracytoplasmatic granules where vasoactive and immunoregulatory mediators including histamine, heparin and cytokines are stored. Several are released in response to aggregation of the high affinity IgE receptor, activation through complement receptors or activation by cytokines.¹² Others, such as tryptase, are both constitutively secreted from MC and released after its activation. Two tryptase genes (α and β) are expressed by human MC. α -(pro) tryptase is secreted constantly from the cell and its levels reflect the total tryptase baseline, which appear to correlate with the MC number.³³ β -tryptase is stored in MC granules and levels are found to be elevated after MC activation, such as anaphylaxis, and are usually otherwise undetectable. Total serum tryptase levels are a reliable non-invasive diagnostic approach to estimate the burden of MC in patients with mastocytosis and allow the distinction between categories of disease.³⁴ In healthy individuals an average 5ng/ml is found (< 15 ng/ml).³³

Symptoms in mastocytosis result from MC-derived mediators and, less frequently, from destructive infiltration of MC [skin, bone marrow, gastrointestinal tract, skeletal, central nervous system (CNS) or lymphoreticular system (spleen, liver and lymph nodes)].³⁷

The MC produce and release a variety of clinically relevant mediators such as histamine, leukotrienes, proteases or heparin (table I). Depending on the type of MC involved, burden of MC, course of disease and co-existing disorders, these mediators may be released to a variable degree resulting in different clinical patterns.³⁸⁻⁴⁰ In some of these patients the symptoms are mild and may not require therapy, in others, they are severe and potentially fatal (urticaria, recurrent flushing, dyspnoea, chest pain, bleeding tendency, peptic ulcer, abdominal pain, severe bone pain, headache, recurrent syncope and hypotensive shock).³⁸⁻⁴⁰

Organ infiltration may occur: without organ dysfunction (B-findings); with impaired organ function (C-findings) or organ failure (table II).

Table I
Clinicopathologic features of mastocytosis associated MC mediators

Clinicopathologic features	Mediator(es)
Systemic	
Vascular instability	Histamine, cysLT, PGD2, PAF
Increased vasopermeability	Histamine, cysLT, PGD2, PAF
Fibrosis	TGF- β
Eosinophilia	IL-5
Lymphocytic infiltration	IL-6, chemokines
Local anticoagulation	Heparin
Fibrinolysis	TPA
Fibrinogenolysis	β -Tryptase
MC hyperplasia	SCF, IL-3, IL-6
Cachexia	TNF- α
Skin	
Pruritus	Histamine
Urticaria	Histamine, LTC4, PAF
Lungs	
Bronchoconstriction	Histamine, cysLT, PGD2, PAF, endothelin
Secretion of mucus	Histamine, LTC4, PGD2
Pulmonar oedema	Histamine, cysLT, PAF
Gastrointestinal Tract	
Gastric Hypersecretion	Histamine
Cramping, abdominal pain	Histamine, cysLT, PAF
Diarrhoea	Histamine
Skeletal System	
Bone Remodelling	Tryptase, chymotryptic proteases, IL-6
Osteoporosis	Heparin, proteases
CNS	
Headache, mood and cognitive changes	Histamine, PGD2

LT, leukotrienes; PG, prostaglandins; PAF, Platelet Activating Factor; TGF, Transforming Growth Factor; IL, interleukin; SCF, Stem Cell Factor; TNF, Tumor Necrosis Factor; TPA, Tissue Type Plasminogen Activator; CNS, Central Nervous System.
Adapted from Valent et al.⁵

CLASSIFICATION

On the basis of recent advances in mastocytosis research, an updated consensus classification for mastocytosis was proposed in 2001 and subsequently adopted by the WHO (table III).⁴¹

The proposed classification is based on formulated criteria. In this concept cutaneous mastocytosis (CM) is based on clinical (urticaria pigmentosa, Darier's sign, mastocytoma) and histological findings (multi/

focal or diffuse infiltrates of MC) together with the absence of criteria that would allow the diagnosis of SM. SM criteria are divided into major criteria (histological and immunohistochemical) and minor criteria (typical cytomorphological and novel biochemical markers) listed in table IV.

The existence of one major and one minor criterion or three minor criteria establish the diagnosis of SM.⁴¹

CLINICAL FEATURES

The occurrence of mastocytosis is usually sporadic. Familial mastocytosis (AD) is a very rare condition with only 50 families recorded in the literature since 1880.²² In up to 15 % of patients the disease is congenital.³⁵

Approximately 65 % of individuals with mastocytosis present with disease in childhood; 55 % of these have manifestations of disease by the age of two. The remaining 35 % that develop the symptoms after puberty are classified as adult onset.³⁶

Most pediatric cases of mastocytosis are asymptomatic or minimally symptomatic with spontaneous resolution during or after adolescence (50 %).⁴² Around 90 % of these patients have isolated cutaneous symptoms, while 10 % have systemic involvement.⁴³ It is, therefore, a benign condition.⁴⁴

Urticaria pigmentosa (UP) is the most common variant of CM.⁴⁵ It usually presents as red-brown macules and papules, often with symmetrical distribution and even anaphylactic reaction after mechanical/thermal stimulation of skin lesions.⁴⁶ In contrast, dermographism is characterised by the appearance of the same lesions after stroking or scratching normal appearing skin. Three rare subvariants of UP have been proposed based on distinct clinical aspects: plaque form, a nodular form and a telangiectasic (*Telangiectasia Macularis Eruptiva Persistans* – TMEP). The younger the patient and the smaller the number of the lesions the higher the probability of spontaneous remission. An adult onset of disease raises the risk of systemic involvement and long persistence.¹⁰ Bullous mastocytosis or Diffuse CM is a very rare and severe variant of CM which usually occurs in the first year of life.⁴⁷ It is characterised by intensely itchy, generalised yellowish, thickened skin with doughy/leathery feel and the appearance of large blisters, sometimes haemorrhagic, spontaneously or following mild trauma due to diffuse MC infiltration.^{45,47} Children with more extensive skin involvement are more likely to exhibit systemic symptoms: flushing, headache, palpitations, abdominal pain, diarrhoea, dyspnoea, wheezing, syncope, hy-

Table II
B and C findings

B-findings	C-findings*	Organ failure
1) High MC burden: Infiltration grade MC of b.m. > 30 % (histology) and serum tryptase > 200 ng/ml		
2) Dysmyelopoiesis: hypercellular marrow; loss of fat cells; myelodysplasia or myeloproliferative; normal blood counts or slight persisting deviation without progression	1) Organopathy (b.m.) Cytopenia/s: ANC < 1000/ μ l Hb < 10 g/dl Plt < 100000/ μ l	Severe progressive pancytopenia ANC < 1000/ μ l Transfusion dependence Plt < 20 000/ μ l
3) Organomegaly: palpable hepatomegaly without ascitis or other signs of organ impairment and/or lymphadenopathy (palpable or visceral LN enlargement found in US or CT (> 2cm)) and/or palpable splenomegaly (without hypersplenism)	2) Organopathy (liver) palpable hepatomegaly with ascitis, abnormal liver function and/or portal hypertension 3) Organopathy (spleen) palpable + hypersplenism 4) Organopathy (Gastrointestinal tract) malabsorption + hypalbuminemia + weight loss 5) Organopathy (skeletal) bone lesions with large osteolysis and/or Severe osteoporosis + pathologic fractures	Progressive deterioration of liver function, loss of appropriate protein synthesis, hepatic coma, severe coagulation disorder

b.m: bone marrow; ANC: absolute neutrophile count; Plt: platelets; LN: lymph node; US: ultrasound; CT: computer tomography.

*C-findings: impaired organ function due to infiltration by neoplastic MC.

Adapted from Valent et al.⁵

potensive shock and death.⁴⁵ Early onset of blisters worsens the prognosis. It is also associated with an increased risk of progression to MCL.⁴⁸ The mastocytoma of the skin presents as a macular, papular or nodular (< 1cm) lesion of yellow, brown or reddish colour. It rarely evolves into SM-AHNMD.⁴⁹

Patients with adult onset mastocytosis generally have evidence of systemic disease (SM). It can follow a benign/indolent course as a persistent clonal disorder (disorder of the bone marrow) or it may be associated with life-threatening haematologic disorders. SM includes four major subtypes: indolent SM (ISM); SM associated with non-mast cell clonal haematological disease (SM-AHNMD); aggressive SM (ASM); and MC Leukemia (MCL).⁴¹ ISM represents 2/3 of all cases of SM and shows a prolonged clinical course (survival time of two decades or more).⁴¹ SM-AHNMD combines two completely different histologies: the MC lineage and non-MC lineage (myelodysplastic syndrome, myeloproliferative syndrome, acute myeloid leukemia, Non-Hodgkin's lymphoma). The haematological disease associated is most frequently (80-90 %) of myeloid lineage.⁴¹ The type of haematologic disorder associated deter-

Table III
WHO classification of Mastocytosis

Variants and subvariants	Abbreviation
Cutaneous Mastocytosis	CM
Maculopapular CM ^a	MPCM/UP
Diffuse or Bullous CM	DCM
Cutaneous Mastocytoma	
Indolent Systemic Mastocytosis	ISM
<i>Smouldering</i> SM	
Isolated bone marrow Mastocytosis	BMM
Systemic Mastocytosis with an Associated clonal haematologic non-MC lineage disease	SM-AHNMD ^b
Aggressive Systemic Mastocytosis with Lymphadenopathic eosinophilia ^c	ASM
MC Leukemia	MCL
Aleukemic MCL ^d	
MC Sarcoma	MCS
Extracutaneous Mastocytoma	

^aalso termed urticaria pigmentosa.

^bthe subtype of AHNMD has to be defined by WHO criteria as well.

^cin a sub-group of these patients, FIP1L1-PDGFRA fusion gene is detectable.

^din these patients circulating MC are less than 10 %.

Adapted from Valent et al.⁵

Table IV
Proposed criteria to diagnose mastocytosis

Cutaneous mastocytosis:	Typical skin lesions = typical clinical signs (UP/MCMP, MCD, mastocytoma) + positive histology with typical infiltrates of MC (diagnostic infiltrate pattern: multi/focal or diffuse)
Systemic mastocytosis: «SM Criteria»	
Major: Multifocal dense infiltrates of MC (> 15 MC aggregating) detected in sections of bone marrow and/or other extracutaneous organ(s) or by tryptase-immunochemistry or other stains	
Minor: a) in bone marrow or other extracutaneous organs MC infiltrates, > 25 % of MC are spindle-shaped/atypical MC (type I and type II) of the bone marrow comprise > 25 % of all MC b) detection of <i>c-kit</i> mutation D816V in bone marrow, blood c) KIT ⁺ MC in bone marrow, blood or extracutaneous organs co-express CD2 or/and CD25 d) serum total tryptase concentrations persistently > 20 ng/ml (not valid in AHNMD)*	
If 1 Major criteria + 1 Minor criteria or 3 Minor criteria = diagnosis of Systemic Mastocytosis	
*In myelodysplasic/myeloproliferative syndromes and acute myeloid leukemia elevated serum tryptase levels have been detected without an increase in MC number or signs of mastocytosis. Adapted from Valent et al. ⁵	

Table V
Diagnostic and Staging methods of Mastocytosis

General Evaluation

Cell blood count (absolute and differential)
Sedimentation rate
Hepatic enzymology
Coagulation parameters
Biochemistry
Alkaline phosphatase
(Consider Hymenopter venom's specific IgE if SM)

Diagnostic Evaluation

Serum tryptase
Skin examination: macroscopic and microscopic (skin biopsy)
Bone marrow aspirate and biopsy:
– Recommended stains: Giemsa, Toluidine Blue; Anti-tryptase; (chloroacetate esterase, Anti-CD25 and CD117 – not specific for MC)
– Histological pattern
– Infiltration pattern
– Cell number and morphology
– b.m. tryptase level
Research of somatic *c-kit* mutation (codon 816 and others)
Serum levels of soluble KIT or CD25

Staging

Chest X-ray
Skeletal X-ray/Scintigraphy
Abdominal US/CT scan
GI endoscopy (with biopsy)
EEG/Neuropsychiatric Evaluation

tients.⁴¹ ASM is characterised by progressive infiltration of various organs with function impairment (severe cytopenias, malabsorption, bone fractures, peripheral eosinophilia, and hepatopathy) but usually without typical skin lesions.⁴¹ The clinical course is variable. MCL is characterized by leukemic infiltration of various organs by immature neoplastic MC. The prognosis is often poor.⁴¹ Localised MC proliferations are extremely rare and include both Extracutaneous Mastocytoma and MC Sarcoma.⁴¹ Mastocytoma is a benign tumour with uniform growth, low grade cytology and good prognosis.⁴¹ MC Sarcoma is a local destructive tumour, usually with poor prognosis.⁴¹

Patients with SM should be followed-up to monitor the development of any signs of disease progression or evolution to AHNMD.

DIAGNOSTIC EVALUATION

Current available diagnostic and staging methods are listed in table V.

Patient's age, clinical findings and laboratory parameters determine the choice of diagnostic and staging methods.

In paediatric patients the disease is usually restricted to the skin and bone marrow examination is not required unless there is late presentation of skin lesions (> 5 years),⁵⁰ organomegaly, significant peripheral blood abnormalities or persistently elevated serum tryptase levels (> 20 ng/ml).^{41,51} In early childhood slightly raised serum tryptase levels might be related with a different ratio of MC granule volume/

mines its prognosis. It is, therefore, important to accurately determine the type of SM in these pa-

Table VI
Practical guide for diagnostic work-up in patients with suspected mastocytosis

Initial sign/symptom	Recommended diagnostic procedures
UP-like skin lesions (paediatric patients)	1. Skin biopsy (with analysis of c-kit D816V) + serum tryptase (monitoring) ^a 2. Bone marrow investigation in cases with suspected hematologic disease/SM
UP-like skin lesions (adult patients)	1. Bone marrow examination + skin biopsy + serum tryptase (> 20 ng/ml in most cases) 2. In case of MS – complete staging ^b
Reported mediator symptoms but no skin lesions (UP) ²	1. Serum tryptase, if > 20 ng/ml – 2 2. Bone marrow examination, if SM – 3 3. SM – staging ^c
Severe unexplained allergic reaction/ Anaphylaxis at presentation	1. Serum tryptase, if > 20 ng/ml – 2 2. Repeat serum tryptase a few weeks later, if serum tryptase > 20 ng/ml – 3 3. bone marrow examination, if SM – 4 4. SM-staging ^c

^aIn young infants, a serum tryptase slightly exceeding 20 ng/ml is not regarded as a safe indicator for SM. Therefore, it is recommended to wait and to monitor the serum tryptase level over time in these patients.

^bComplete staging: gastrointestinal tract, skeleton (X-ray, scintigraphy), abdomen US, complete blood count, serum chemistry, coagulation, c-kit mutations.

^cEspecially in patients with aggressive MC disorders, skin lesions are absent. Therefore, it is of pivotal importance to know the subtype of SM in these patients as soon as possible. In ASM serum tryptase level is usually higher than in patients with isolated bone marrow mastocytosis (often < 20 ng/ml), a benign MC disease in which skin lesions are also absent.

Adapted from Valent et al.⁶

total body volume and total volume of skin MC/total body volume, compared with adults.²⁸

Therefore, consideration should be given to monitoring the serum tryptase level over time and to not perform a bone marrow puncture unless there are suggesting signs of systemic disease.

The existence of more than 15 MC per aggregate (diffuse or multifocal infiltrates with a significant percentage of spindle-shape cells) fulfils the diagnosis of SM.⁵² If the majority of MC are round it is necessary to investigate additional criteria because such accumulations have been detected in reactive MC hyperplasia (parasite infections neoplastic disorders, aplastic anemia, and chronic inflammatory diseases), SCF-treated patients and myeloid leukemia without mastocytosis.⁴¹

We present a practical guide for diagnostic work-up in patients with suspected mastocytosis in table VI. Figure 1 shows a diagnostic algorithm discriminating mastocytosis variants.

DIFFERENTIAL DIAGNOSIS

SM symptoms, in the absence of skin lesions, are often non-specific and thus confused with other underlying conditions namely: endocrine (adrenal tumour, gastrinoma, VIPoma, carcinoid syndrome), cardiovascular (idiopathic anaphylaxis, cardiac disease,

aortic stenosis, vasculitis, essential hypertension), gastrointestinal (peptic ulcer, ulcerative colitis, hepatitis, parasite disease, gluten-sensitive enteropathy), pulmonary, allergic, infectious, immunologic, rheumatologic and oncologic.^{41,10}

However, one should be alert to the possibility of MC disease when patients present “inexplicable” symptoms that might be related with MC-mediator release such as vascular instability, anaphylactic shock, flushing, diarrhoea and headache, even if no skin lesions are found.

TREATMENT

It is consensual, since no curative therapies are available, that mastocytosis should be treated according to the symptoms presented.^{53,54}

In patients with predominant mediator-release symptoms, “mediator-targeting” drugs must be prescribed in addition to avoidance of triggers of MC degranulation^{53,54} (table VII).

Commonly used medication includes anti-histamines (H1/H2), MC stabilisers, acetylsalicylic acid (aspirin), ketotifen or adrenaline. Aspirin is used for flushing, tachycardia and syncope.⁵⁵ Ketotifen has been recommended for bone pain and/or flushing.^{56,57} Gastric ulcerative disease requires the use of H2 anti-histamines or a proton pump inhibitor.⁵⁶ In

Fig. 1.—Diagnostic algorithm of mastocytosis.

many patients a combination of H1 and H2 anti-histamines is administered. Low dose of corticosteroids

may relieve malabsorption and ascitis.⁵⁶ Self administered epinephrine is indicated in recurrent anaphylac-

tic episodes.^{53,54} Specific immunotherapy for hymenoptera venom might be considered in patients with SM.⁵⁸ Cutaneous lesions may show good (transient) response to Psoralen-PhotoChemotherapy (PUVA)⁵⁹ or local corticosteroids.

In case of rapid or aggressive disease progression cytoreductive drugs are recommended: α -interferon, with or without corticosteroids, or cladribine.^{54,55} If no benefit is achieved one should consider experimental poly-chemotherapy or bone marrow transplant (haematopoietic stem cells).²⁸ Although these modalities can render significant MC reduction and symptom control in some patients, responses are transient and the prognosis remains unchanged.⁵¹

In patients with significant splenomegaly and hypersplenism, splenectomy may be considered.⁶⁰

Surgical excision and consecutive radiation and/or high-dose chemotherapy should be considered in patients with MC sarcoma.

Future strategies are presently focused on the identification of molecular/genetic markers and potential drug targets in neoplastic MC. Investigation is addressed to targeted-drugs such as: tyrosine kinase inhibitors (imatinib mesilate, AMN107, dasatinib, PKC412), non tyrosine kinase kit signalling inhibitors (geldanamycin, bortezomib, rapamycin) and monoclonal antibodies (denileukine diftitox, gemtuzumab ozogamicin).⁶¹ O imatinib mesilate is currently the only such drug approved by the Food and Drug Administration (FDA) that might be useful in SM (ASM) associated to gene defects such the FIP1L1-PDGFR fusion gene^{62,63} and others (excluding the c-kit mutation of D816V).⁶⁴

Preliminary data of a study conducted by Carter et al demonstrates that anti-IgE therapy (omalizumab) may have efficacy in preventing anaphylaxis in patients with SM resulting from reduction of MC survival and overaccumulation.⁶⁵

CASE REPORT

We present a case report of an 18 month-year-old, caucasian girl. She had a dystocic birth at 37 weeks and neonatal hypoxic-ischemic encephalopathy with hypotension. She is a child of non-consanguineal parents and with maternal history of atopic dermatitis and latex allergy.

At four months of age the child exhibited a pruriginous microvesicular rash of the neck. It was diagnosed as atopic dermatitis and treated accordingly. However, there was a progressive worsening, showing extension of skin lesions to the trunk. Six months later she developed an erythematous rash of the face and trunk followed by respiratory distress and

Table VII

Triggering factors that induce release of MC mediators in patients with mastocytosis

-
- Insect stings, venoms (hymenoptera, jellyfish, snake)
 - Food (shellfish, hot or alcoholic beverages, spices, cheese)
 - Drugs (opioids, dextran, radiocontrasts, adrenergic and cholinergic receptor antagonists, AAS and NSADs, local anesthetics)
 - Alcohol
 - Mechanical irritation (friction, pressure)
 - Emotional or physical stress (exercise)
 - Sudden temperature changes, prolonged heat or cold
 - Infection (viral, bacterial)
-

respiratory arrest and syncope. The child's mother gave her a cold bath with immediate recovery. She was treated with intravenous corticosteroid and oral anti-histamine in the emergency department. Apparently there was no prior episode of fever, cold symptoms, insect stings, trauma, sudden/intense temperature changes or histamine-release food/drink ingestion. Less than 24 hours after hospital discharge, a bullous dermatosis with transparent fluid of the face, neck and trunk started along with dyspnoea. She was taken to the hospital and remained admitted for 2 weeks, showing total remission under treatment with adrenaline, oral and topical corticosteroids, hydroxyzine, ketotifen and flucloxaciline. The skin biopsy confirmed the diagnosis of mastocytosis.

Laboratory work-up showed raised levels of serum tryptase (381 ng/ml) and total IgE (1138 KU/L). Complete blood cell count, peripheral blood smear, serum biochemistry, skeletal X-ray, and abdominal ultrasound were all normal. Posterior evaluation showed a significant reduction of serum tryptase level to 25ng/ml. The absence of persistent significantly raised levels of serum tryptase, organomegalies and skeletal or peripheral blood anomalies eliminated the indication for bone marrow biopsy/puncture.

No further anaphylactic episodes occurred. However, daily episodes of flushing and urticaria elicited by heat, pressure and friction are noticed even under regular treatment with cetirizine, disodium cromoglycate, ketotifen and avoidance of trigger factors of MC mediator-release.

There were no side effects of therapy nor a need for use of self-administered epinephrine prescribed.

Physical examination revealed urticarial skin lesions in areas that suffered pressure, resulting from child's handling. The remaining skin had a normal aspect and texture.

The c-kit mutation research is in progress.

CONCLUSIONS

During the last few years, major advances in mastocytosis research have been made. Thus, by using defined criteria it is now possible to discriminate between MC disorders and other systemic diseases.

Mastocytosis is a relatively rare disorder, but its diagnosis is of relevance because of the multiple clinical manifestations and due to the risk of associated symptoms.

Although pediatric mastocytosis is usually benign, sometimes it can be clinically exuberant or severe and with a difficult diagnostic approach. Multidisciplinary work is therefore essential in order to diagnose, treat and manage the disease.

ACKNOWLEDGMENTS

The authors would like to thank to Dr. Orquídea Freitas (Hematology Unit of Dona Estefânia Hospital), Dr. Margarida Lima (Hematology Department of Santo António do Porto Hospital) and Dra. Susana Machado (Dermatology Department of Santo António do Porto Hospital) for the information and enlightening given concerning the clinical case reported.

REFERENCES

1. Nettleship E, Tay W. Rare forms of urticaria. *Br Med J* 1869; 2:323-30.
2. Unna PG. Beitrage zur anatomie und pathogeneses der urticaria simplex und pigmentosa. *Mschr Prakt Dermat Studien* 1887;3H:1.
3. Ellis JM. Urticaria pigmentosa. A report of a case with autopsy. *AMA Arch Pathol* 1949;48:426-9.
4. Horny H-P, Sotlar K, Valent P. Mastocytosis: state of the art. *Pathobiology* 2007;74:121-132.
5. Castells M. Mastocytosis: classification, diagnosis and clinical presentation. *Allergy Asthma Proc* 2004;25:33-36.
6. Fernández AT, Campoamor LN, Mora LE, Zambrano AZ. Diagnóstico, tratamiento y clasificación de la mastocitosis pediátrica. Estudio de 172 casos. *Actas Dermosifiliogr* 1998;89: 461-476.
7. Rosbotham JL, Malik NM, Syrris P, Jeffery S, Bedlow A, Gharraie S et al. Lack of c-kit mutation in familial urticaria pigmentosa. *Br J Dermatol* 1999;140:849-852.
8. Golkar L, Bernhar JD. Mastocytosis. *Lancet* 1997;349: 1379-1385.
9. Valent P, Sillaber C, Bettelheim P. The growth and differentiation of mast cells. *Prog Growth Factor Res* 1991;3:27-41.
10. Valent P, Akim C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R et al. Mastocytosis: Pathology, genetics, and current opinions for therapy. *Leukemia and Lymphoma* 2005;46(1):35-48.
11. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit + and expresses aminopeptidase N (CD13). *Blood* 1999;94: 2333-2342.
12. Valent P. The riddle of the mast cell: c-kit ligand as missing link? *Immunol. Today* 1994;15:111-114.
13. Sperr WR, Escobano L, Jordan JH, Scherthaner GH, Kundl M, Horny H-P et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. *Leuk Res* 2001;25: 529-36.
14. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzunaki H et al. Effects of T-helper 2-type cytokines, interleukin-3(IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. *Blood* 2005;86:3705-14.
15. Godfrain C, Louaed J, Faulkner H, Vink A, Warnier G, Grecis R et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea and kidneys of IL-9 transgenic mice. *J Immunol* 1998; 160:3989-96.
16. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. *J Exp Med* 1991;173:507-10.
17. Tagaya Y, Burton JD, Miyamoto Y, Waldmann TA. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. *Embo J* 1996;15:4928-39.
18. Valent P, Spanblöchl E, Sperr WR, Sillaber Ch, Agis H, Zsebo K et al. Induction of differentiation human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture. *Blood* 1992;80:2237-45.
19. Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor and mast cells. What each is teaching us about the others. *Am J Pathol* 1993;142:965-74.
20. Feger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M. Kit and c-kit mutations in mastocytosis: a short overview with especial reference to novel molecular and diagnostic concepts. *Int Arch Allergy Immunol*;127:110-14.
21. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Susuki Y. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated haematologic disorder. *Proc Natl Acad Sci (USA)* 1995;92:10560-64.
22. Longley BJ, Metcalf DD, Sharp M, Wang, Tyrrel L, Lu S-Z et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis. *Proc Natl Acad Sci (USA)* 1999;96:1609-14.
23. Büttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-kit mutation in adult, but not childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behaviour. *J Invest Dermatol* 1998;111:1227-31.
24. Yavuz AS, Lipsky PE, Yavus S, Metcalfe DD, Akin C. Evidence for the involvement of an hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutation in the c-kit gene. *Blood* 2002;100:661-65.
25. Ferrão PT, Gonda TJ, Ashman LK. Constitutively active mutant D816VKit induces megakaryocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. *Leuk Res* 2003;27:547-55.
26. Swolin B, Rodger S, Roupe G. Cytogenetic studies in patients with mastocytosis. *Cancer Genet Cytogenet* 2000;120:131-135.
27. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV et al. A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. *Leuk Res* 2006;30:373-78.
28. Valent P, Sperr WR, Schwart LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell haematopoietic neoplasms. *J Allergy Clin Immunol* 2004;114:3-11.
29. Metcalfe DD, Akin C. Mastocytosis: molecular mechanisms and clinical disease heterogeneity. *Leuk Res* 2001;25: 577-584.

30. Yanagihori H, Oyama N, Nakamura K, Kaneko F. c-kit mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. *J Mol Diagn* 2005;7:252-7.
31. Scherthner GH, Jordan JH, Ghannadan M, Agis H, Bevec D, Nuñez R et al. Expression, epitope analysis and functional role of the LFA-2 antigen detectable on neoplastic mast cells. *Blood* 2001;98:3784-92.
32. Escribano L, Díaz-Agustín B, Bellas C, Navalón R, Nuñez R, Sperr WR et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. *Leuk Res* 2001;25:563-70.
33. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al. The Alfa form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. *J Clin Invest* 1995;96:2702-10.
34. Sperr WR, Jordan JH, Fiegl M, Escribano L, Dirnhofer S, Semper H et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. *Int Arch Allergy Immunol* 2002;128:136-141.
35. Azana JM, Torrelo A, Mediero IG, Zambrano A. Urticaria pigmentosa: a review of 67 paediatric cases. *Ped Dermatol* 1994;11:102-106.
36. Kettelhut BV, Metcalf DD. Paediatric mastocytosis. *Ann Allergy* 1994;73:197-207.
37. Kettelhut BV, Metcalf DD. Paediatric mastocytosis. *J Invest Dermatol* 1991;96:15-18S.
38. Hansen U, Wiese R, Knolle J. Shock and coagulation disorders in systemic mastocytosis. *Dtsch Med Wochenschr* 1994;119:1231-4.
39. Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. *Hematol Oncol Clin North Am* 2000;14:579-623.
40. Campbell EW, Hector D, Gossin V. Heparin activity in systemic mastocytosis. *Ann Int Med* 1979;90:940-1.
41. Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. *Leuk Res* 2001;25:603-625.
42. Hartmann K, Metcalf DD. Paediatric mastocytosis. *Hematol Oncol Clin North Am* 2000;14:625-40.
43. Shiloh-Malawsky Y, Confino Y, Yosipovitz A, Nassan D, Augarten A. Mastocytosis: The paediatric emergency physician's perspective. *Pediatr Emerg Care* 2003;19:172-3.
44. Carter MC, Metcalf DD. Paediatric mastocytosis. *Arch Dis Child* 2002;86:315-9.
45. Soter NA. Mastocytosis and the skin. *Hematol Oncol Clin North Am* 2000;14:557.
46. Topar G, Staudacher C, Geisen F, Gabl C, Fend F, Herald M et al. Urticaria pigmentosa: a clinical hematopathologic and serologic study of 30 adults. *Am J Clin Pathol* 1998;109:279-85.
47. Hartmann K, Henz BM. Mastocytosis: recent advances in defining the disease. *Br J Dermatol* 2001;144:682-95.
48. Orkin M, Good RA, Clawson C, Fisher I, Windhorst D. Bullous mastocytosis. *Arch Dermatol* 1970;101:547-74.
49. Wolff K, Komar M, Petzelbauer P. Clinical and pathological aspects of cutaneous mastocytosis. *Leuk Res* 2001;25:603-625.
50. Holly C, Shaffer BS, Daniel J et al. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a paediatric patient: Case report and literature review. *J Am Acad Dermatol* 2006;54:S210-3.
51. Akin C, Metcalfe DD. Systemic mastocytosis. *Annu. Rev. Med.* 2004;55:419-32.
52. Horny H-P, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria and immunohistochemical findings. *Leuk Res* 2001;25:543-551.
53. Valent P, Akin C, Sperr WR, Horny H-P, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. *Br J Haematol* 2003;122:1-23.
54. Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD. Mastocytosis: current concepts in diagnosis and treatment. *Ann Hematol* 2002;81:677-90.
55. Roberts LJ, Sweetman BJ, Lewis RA, Austen KF, Oates JA. Increased production of prostaglandin D2 in patients with systemic mastocytosis. *N Engl J Med* 1980;303:1400-4.
56. Metcalfe DD. The treatment of mastocytosis. *J Invest Dermatol* 1991;96:64S.
57. Pova P, Ducla-Soares J, Fernandes A, Palma Carlos AG. A case of systemic mastocytosis; therapeutic efficacy of ketotifen. *J Intern Med* 1991;229:475-7.
58. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. *Current Opin Allergy Clin Immunol* 2006;6(4):284-8.
59. Godt O, Proksch E, Streit V, Christophers E. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. *Dermatology* 1997;195:35-9.
60. Friedman B, Darling G, Norton J, Hamby L, Metcalfe DD. Splenectomy in management of systemic mast cell disease. *Surgery* 1990;107:94-100.
61. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Novel approaches in the treatment of systemic mastocytosis. *Cancer* 2006;107:1429-39.
62. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL et al. FIP1L1-PDGFR fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood* 2004;104:3038-45.
63. Zermati Y, De Sepulveda P, Feger P, Letard S, Kersual J, Castellan N et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cells neoplasms. *Oncogene* 2003;22:660-4.
64. Tefferi A. Treatment of systemic mast cell disease: beyond interferon. *Leuk Res* 2004;28:223-4.
65. Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Ménéière disease with anti-IgE therapy. *J Allergy Clin Immunol* 2007;120:213-5.